J Urol Oncol.
2024 Mar;22(1):78-94. 10.22465/juo.244600020001.
Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients
- Affiliations
-
- 1University of Southern California Keck School of Medicine, Department of Population and Public Health Sciences, Los Angeles, CA, USA
- 2University of Southern California Keck School of Medicine, Department of Anesthesiology, Los Angeles, CA, USA
- 3South Dakota School of the Mines, Department of Engineering, Rapid City, SD, USA
- 4Kaiser Permanente School of Medicine, Department of Research and Evaluation, Pasadena, CA, USA
- 5University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center, Department of Urology, Los Angeles, CA, USA
- 6University of Southern California Keck School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
- KMID: 2553948
- DOI: http://doi.org/10.22465/juo.244600020001
Abstract
- Purpose
Diabetes mellitus, a frequent comorbid condition in cancer patients, has been shown to increase risk of all-site cancer mortality. This relationship has not been systematically studied in bladder cancer patients. This systematic review and meta-analysis aimed to identify, evaluate, and synthesize available evidence on the relationship between history of diabetes and outcomes in bladder cancer patients.
Materials and Methods
Systematic searches interrogated OVID MEDLINE, Embase, Web of Science, Google Scholar, and Cochrane Library to identify scholarly reports relating diabetes to all-cause mortality, bladder cancer-specific mortality, recurrence, and progression in bladder cancer patients. After critical review, meta-analysis was used to quantitively synthesize qualifying data and assess potential influence of publication bias, clinical heterogeneity, and residual confounding.
Results
We synthesized data on over 226,472 patients treated with curative intent uniquely represented in 28 studies that met quality metrics. Having diabetes was positively associated with each outcome. Hazard ratio estimates were indistinguishable for mortality from any cause, 1.22 (95% confidence interval [CI], 1.12–1.33) and bladder cancer-specific mortality, 1.28 (95% CI 1.17–1.41) and notably stronger in patients with muscle-invasive and high-risk non–muscle-invasive bladder cancer, 1.32 (95% CI, 1.15–1.50) and 1.48 (95% CI, 1.06–2.06). Neither publication bias, systematic error, nor confounding by factors such as smoking or obesity is likely to explain the observed associations.
Conclusions
Bladder cancer patients with diabetes experience elevated mortality that is not explained by diabetes-related comorbidities or complications. Future research should explore type, severity, and duration of diabetes in relation to unfavorable bladder cancer outcomes.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies
- Systematic review and meta-analysis of cancer risks in relation to environmental waste incinerator emissions: a meta-analysis of case-control and cohort studies
- Genetic and Epigenetic Alterations in Bladder Cancer
- Effects of Vitamin and Antioxidant Supplements in Prevention of Bladder Cancer: a Meta-Analysis of Randomized Controlled Trials
- Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
